Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
Status:
Recruiting
Trial end date:
2024-10-20
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the safety and feasibility of neoadjuvant tislelizumab combined
with chemoradiotherapy in patients with resectable esophageal squamous cell cancer. The tumor
microenvironment and circulating immunological biomarkers in these patients were further
evaluated to explore the factors affecting the efficacy of neoadjuvant therapy for esophageal
cancer. This study will provide valuable information for further prospective clinical trials
of neoadjuvant anti-PD-1 and other immunotherapy in esophageal cancer patients.